Dr. Feldman has received consultant fees, speaking fees, and/or honoraria (less than $10,000) from Novartis.
Parents' preferences for drug treatments in juvenile idiopathic arthritis: A discrete choice experiment
Article first published online: 27 AUG 2012
Copyright © 2012 by the American College of Rheumatology
Arthritis Care & Research
Volume 64, Issue 9, pages 1382–1391, September 2012
How to Cite
Burnett, H. F., Regier, D. A., Feldman, B. M., Miller, F. A. and Ungar, W. J. (2012), Parents' preferences for drug treatments in juvenile idiopathic arthritis: A discrete choice experiment. Arthritis Care Res, 64: 1382–1391. doi: 10.1002/acr.21698
- Issue published online: 27 AUG 2012
- Article first published online: 27 AUG 2012
- Accepted manuscript online: 13 APR 2012 12:07PM EST
- Manuscript Accepted: 26 MAR 2012
- Manuscript Received: 21 DEC 2011
- Ontario Ministry of Health and Long-Term Care Drug Innovation Fund
- The Hospital for Sick Children Research Institute
- Canadian Institutes of Health Research
To examine parents' preferences for drug treatments and health outcomes in juvenile idiopathic arthritis (JIA) and identify demographic and health-related factors that significantly impact choice.
A discrete choice experiment was conducted with 105 parents of children with JIA who were cared for by a rheumatologist at The Hospital for Sick Children in Canada. Attributes evaluated included “drug treatment,” “child reported pain from arthritis,” “participation in daily activities,” “side effects,” “days missed from school,” and “cost to you.” Multinomial logit regression was used to estimate the relative importance of each attribute level and interaction term.
Parents made tradeoffs between characteristics of the drug treatments and health outcomes. “Participation in daily activities” was the most important attribute, followed by “child reported pain from arthritis” and “cost to you.” Parents of children with longer disease durations had stronger preferences for improved participation in daily activities, whereas parents of older JIA patients had stronger preferences for improved control of pain.
Parents of children with JIA demonstrated strong preferences for treatments that reduce pain and improve daily functioning regardless of the associated side effects, level of responsibility required for drug administration, and days missed from school. Parents of children with longer disease durations and those who had been prescribed aggressive therapies had a greater preference for treatment effectiveness. These findings support the need for considering parental preferences in decisions regarding the choice of treatment for JIA.